PARP inhibitors, such as olaparib, rucaparib, and niraparib, have been approved for the treatment of cancers with BRCA mutations, including ovarian, breast, pancreatic, and prostate cancers. These drugs are particularly effective in patients with tumors that have defective DNA repair mechanisms, as they selectively target cancer cells while sparing normal cells.
